W. Luo, E. Ko, J. Hsu, X. Wang, and S. Ferrone, Targeting Melanoma Cells with Human High Molecular Weight-Melanoma Associated Antigen-Specific Antibodies Elicited by a Peptide Mimotope: Functional Effects, The Journal of Immunology, vol.176, issue.10, pp.6046-6054, 2006.
DOI : 10.4049/jimmunol.176.10.6046

L. Gattinoni, D. Powell, . Jr, S. Rosenberg, and N. Restifo, Adoptive immunotherapy for cancer: building on success, Nature Reviews Immunology, vol.115, issue.5, pp.383-393, 2006.
DOI : 10.1038/nri1842

Y. Akiyama, K. Maruyama, N. Nara, T. Mochizuki, and A. Yamamoto, Cytotoxic T cell induction against human malignant melanoma cells using HLA- A24-restricted melanoma peptide cocktail, Anticancer Res, vol.24, pp.571-577, 2004.

P. Coulie, V. Karanikas, D. Colau, C. Lurquin, and C. Landry, A monoclonal cytolytic T-lymphocyte response observed in a melanoma patient vaccinated with a tumor-specific antigenic peptide encoded by gene MAGE-3, Proceedings of the National Academy of Sciences, vol.98, issue.18, 2001.
DOI : 10.1073/pnas.161260098

D. Godelaine, J. Carrasco, S. Lucas, V. Karanikas, and B. Schuler-thurner, Polyclonal CTL Responses Observed in Melanoma Patients Vaccinated with Dendritic Cells Pulsed with a MAGE-3.A1 Peptide, The Journal of Immunology, vol.171, issue.9, pp.4893-4897, 2003.
DOI : 10.4049/jimmunol.171.9.4893

S. Shu, A. Cochran, R. Huang, D. Morton, and H. Maecker, Immune responses in the draining lymph nodes against cancer: Implications for immunotherapy, Cancer and Metastasis Reviews, vol.10, issue.1, pp.233-242, 2006.
DOI : 10.1007/s10555-006-8503-7

C. Cormary, E. Hiver, B. Mariame, G. Favre, and A. Tilkin-mariame, Coexpression of CD40L and CD70 by semiallogenic tumor cells induces anti-tumor immunity, Cancer Gene Therapy, vol.268, issue.12, pp.963-972, 2005.
DOI : 10.1038/sj.cgt.7700861

G. Dunn, A. Bruce, H. Ikeda, L. Old, and R. Schreiber, Cancer immunoediting: from immunosurveillance to tumor escape, Nature Immunology, vol.3, issue.11, pp.991-998, 2002.
DOI : 10.1038/ni1102-991

C. Cormary, R. Gonzalez, J. Faye, G. Favre, and A. Tilkin-mariame, Induction of T-cell antitumor immunity and protection against tumor growth by secretion of soluble human CD70 molecules, Cancer Gene Therapy, vol.11, issue.7, pp.497-507, 2004.
DOI : 10.1038/sj.cgt.7700708

D. Sojka, M. Donepudi, J. Bluestone, and M. Mokyr, Melphalan and Other Anticancer Modalities Up-Regulate B7-1 Gene Expression in Tumor Cells, The Journal of Immunology, vol.164, issue.12, pp.6230-6236, 2000.
DOI : 10.4049/jimmunol.164.12.6230

S. Coral, L. Sigalotti, M. Altomonte, A. Engelsberg, and F. Colizzi, 5-aza- 29-deoxycytidine-induced expression of functional cancer testis antigens in human renal cell carcinoma: immunotherapeutic implications, Clin Cancer Res, vol.8, pp.2690-2695, 2002.

Y. Hori, A. Kikuchi, M. Isomura, M. Katayama, and Y. Miura, Posttranslational modifications of the C-terminal region of the rho protein are important for its interaction with membranes and the stimulatory and inhibitory GDP/GTP exchange proteins, Oncogene, vol.6, pp.515-522, 1991.

M. Bredel, I. Pollack, J. Freund, A. Hamilton, and S. Sebti, Inhibition of Ras and Related G-Proteins As a Therapeutic Strategy for Blocking Malignant Glioma Growth, Neurosurgery, vol.43, issue.1, pp.124-131, 1998.
DOI : 10.1097/00006123-199807000-00081

C. Allal, A. Pradines, A. Hamilton, S. Sebti, and G. Favre, Farnesylated RhoB Prevents Cell Cycle Arrest and Actin Cytoskeleton Disruption Caused by the Geranylgeranyltransferase I Inhibitor GGTI-298, Cell Cycle, vol.1, issue.6, pp.430-437, 2002.
DOI : 10.4161/cc.1.6.272

T. Kusama, M. Mukai, M. Tatsuta, Y. Matsumoto, and H. Nakamura, Selective inhibition of cancer cell invasion by a geranylgeranyltransferase-I inhibitor, Clinical and Experimental Metastasis, vol.20, issue.6, pp.561-567, 2003.
DOI : 10.1023/A:1025898316728

J. Lu, L. Chan, H. Fiji, R. Dahl, and O. Kwon, In vivo antitumor effect of a novel inhibitor of protein geranylgeranyltransferase-I, Molecular Cancer Therapeutics, vol.8, issue.5, pp.1218-1226, 2009.
DOI : 10.1158/1535-7163.MCT-08-1122

S. Reinke, P. Koniger, G. Herberth, H. Audring, and H. Wang, Differential Expression of MART-1, Tyrosinase, and SM5-1 in Primary and Metastatic Melanoma, The American Journal of Dermatopathology, vol.27, issue.5, pp.401-406, 2005.
DOI : 10.1097/01.dad.0000180076.17932.ee

H. Benlalam, V. Vignard, A. Khammari, A. Bonnin, and Y. Godet, Infusion of Melan-A/Mart-1 specific tumor-infiltrating lymphocytes enhanced relapse-free survival of melanoma patients, Cancer Immunology, Immunotherapy, vol.175, issue.4, pp.515-526, 2007.
DOI : 10.1007/s00262-006-0204-0

B. Seliger, U. Wollscheid, F. Momburg, T. Blankenstein, and C. Huber, Characterization of the major histocompatibility complex class I deficiencies in B16 melanoma cells, Cancer Res, vol.61, pp.1095-1099, 2001.

W. Yokoyama, S. Maxfield, and E. Shevach, Very Early (VEA) and Very Late (VLA) Activation Antigens have Distinct Functions in T Lymphocyte Activation, Immunological Reviews, vol.1988, issue.1, pp.153-176, 1989.
DOI : 10.1084/jem.165.6.1725

R. Botella-estrada, M. Escudero, O. Connor, J. Nagore, E. Fenollosa et al., Cytokine production by peripheral lymphocytes in melanoma, Eur Cytokine Netw, vol.16, pp.47-55, 2005.

E. Aktas, U. Kucuksezer, S. Bilgic, G. Erten, and G. Deniz, Relationship between CD107a expression and cytotoxic activity, Cellular Immunology, vol.254, issue.2, pp.149-154, 2009.
DOI : 10.1016/j.cellimm.2008.08.007

P. Hersey, Z. Si, M. Smith, and W. Thomas, Expression of the co-stimulatory molecule B7 on melanoma cells, International Journal of Cancer, vol.128, issue.4, pp.527-532, 1994.
DOI : 10.1002/ijc.2910580413

G. Sarrabayrouse, C. Synaeve, K. Leveque, G. Favre, and A. Tilkin-mariame, Statins Stimulate In Vitro Membrane FasL Expression and Lymphocyte Apoptosis through RhoA/ROCK Pathway in Murine Melanoma Cells, Neoplasia, vol.9, issue.12, pp.1078-1090, 2007.
DOI : 10.1593/neo.07727

M. Pittet, D. Valmori, P. Dunbar, D. Speiser, and D. Lienard, T Cells in a Large Proportion of Human Histocompatibility Leukocyte Antigen (Hla)-A2 Individuals, The Journal of Experimental Medicine, vol.59, issue.5, 1999.
DOI : 10.1097/00002371-199601000-00009